Screener
ADMA Biologics ADMA Total Assets
Total Assets at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Deferred tax assets, net | 69,965 | 73,261 |
| Right-of-use assets | 6,146 | 6,650 |
| Deposits and other assets | 9,127 | 8,600 |
| TOTAL ASSETS | $$684,210 | 624,242 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $$31,724 | 22,519 |
| Accrued expenses and other current liabilities | 39,105 | 40,466 |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's total assets?
- ADMA Biologics (ADMA) reported total assets of $684.21M in Q2 2026.
- How has ADMA Biologics's total assets changed year-over-year?
- ADMA Biologics's total assets increased by 22.5% year-over-year, from $558.38M to $684.21M.
- What is the long-term trend for ADMA Biologics's total assets?
- Over 5 years (2020 to 2025), ADMA Biologics's total assets has grown at a 24.6% compound annual growth rate (CAGR), from $207.67M to $624.24M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about ADMA Biologics's total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude